drugset / Trial / NCT01733992

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

NCT01733992 ↗

Phase 1 Completed 36 enrolled Rigel Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of R348 eye drops in patients with dry eye disease.

Timeline

Start
2012-11
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator R348 Small molecule 0.2 % Other
Comparator R348 Small molecule 0.5 % Other
Comparator R348 Small molecule 1 % Other

Indications